Hikma temporarily suspends launch of generic Advair Diskus
Hikma Pharmaceuticals said on Friday that it had temporarily paused the launch of its generic version of GlaxoSmithKline's asthma treatment, Advair Diskus.
The US Food and Drug Administration approved Hikma's Abbreviated New Drug Application (ANDA) for generic Advair Diskus in December 2020. However, the company has since submitted an amendment to the application, which reflects enhanced packaging controls to meet new industry standards adopted since the initial submission of its ANDA application.
HIkma said the amendment will be classified as a Prior Approval Supplement and will not affect the approved status of the company’s ANDA for generic Advair Diskus.
"Hikma will work closely with the FDA in its review and will commence distribution of the product once the review has been completed," it said.
Important Legal Notice about News Sources: Pilling and Co Stockbrokers Ltd. is not responsible for the content or accuracy of third party news and we may not share the views of the author or publisher. We provide third party news for your convenience and information only and make no representation or endorsement whatsoever and hereby exclude all liability for any loss or damage that may be incurred by you as a result of your access or use. Please note that third party content may be subject to terms and conditions imposed by the third party owner of that content.